S&P 500   4,280.15
DOW   33,761.05
QQQ   330.39
Sinema took Wall Street money while killing tax on investors
A Hot Tech Company With Strong Patents & Partners (Ad)pixel
Expanded IRS free-file system one step closer in Dems' bill
Climate bill: Could coal communities shift to nuclear?
Germans urged to cap heat in offices this winter to save gas
Biden & Bill Gates Igniting $40 Trillion Heist? (Ad)
The 7 Types Of People Every Entrepreneur Needs In Their Inner Circle -- And How To Find Them
Former Deutsche Bank Co-CEO Anshu Jain dies
Germany urged to cap heat in offices this winter to save gas
Biden & Bill Gates Igniting $40 Trillion Heist? (Ad)
S&P 500   4,280.15
DOW   33,761.05
QQQ   330.39
Sinema took Wall Street money while killing tax on investors
A Hot Tech Company With Strong Patents & Partners (Ad)pixel
Expanded IRS free-file system one step closer in Dems' bill
Climate bill: Could coal communities shift to nuclear?
Germans urged to cap heat in offices this winter to save gas
Biden & Bill Gates Igniting $40 Trillion Heist? (Ad)
The 7 Types Of People Every Entrepreneur Needs In Their Inner Circle -- And How To Find Them
Former Deutsche Bank Co-CEO Anshu Jain dies
Germany urged to cap heat in offices this winter to save gas
Biden & Bill Gates Igniting $40 Trillion Heist? (Ad)
S&P 500   4,280.15
DOW   33,761.05
QQQ   330.39
Sinema took Wall Street money while killing tax on investors
A Hot Tech Company With Strong Patents & Partners (Ad)pixel
Expanded IRS free-file system one step closer in Dems' bill
Climate bill: Could coal communities shift to nuclear?
Germans urged to cap heat in offices this winter to save gas
Biden & Bill Gates Igniting $40 Trillion Heist? (Ad)
The 7 Types Of People Every Entrepreneur Needs In Their Inner Circle -- And How To Find Them
Former Deutsche Bank Co-CEO Anshu Jain dies
Germany urged to cap heat in offices this winter to save gas
Biden & Bill Gates Igniting $40 Trillion Heist? (Ad)
S&P 500   4,280.15
DOW   33,761.05
QQQ   330.39
Sinema took Wall Street money while killing tax on investors
A Hot Tech Company With Strong Patents & Partners (Ad)pixel
Expanded IRS free-file system one step closer in Dems' bill
Climate bill: Could coal communities shift to nuclear?
Germans urged to cap heat in offices this winter to save gas
Biden & Bill Gates Igniting $40 Trillion Heist? (Ad)
The 7 Types Of People Every Entrepreneur Needs In Their Inner Circle -- And How To Find Them
Former Deutsche Bank Co-CEO Anshu Jain dies
Germany urged to cap heat in offices this winter to save gas
Biden & Bill Gates Igniting $40 Trillion Heist? (Ad)
NASDAQ:KIN

Kindred Biosciences - KIN Stock Forecast, Price & News

Notice: This company has been marked as potentially delisted and may not be actively trading.
Add
Compare
Today's Range
N/A
50-Day Range
$9.08
$9.25
52-Week Range
N/A
Volume
178,496 shs
Average Volume
840,890 shs
Market Capitalization
$420.52 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
KIN stock logo

About Kindred Biosciences (NASDAQ:KIN) Stock

Kindred Biosciences, Inc. is a development-stage biopharmaceutical company, which focuses on saving and improving the lives of pets. The company was founded by Richard Chin and Denise M. Bevers on September 25, 2012 and is headquartered in Burlingame, CA.

Receive KIN Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Kindred Biosciences and its competitors with MarketBeat's FREE daily newsletter.

KIN Stock News Headlines

Memphis People in Business: Feb. 24, 2022
ObsEva gains after naming chief strategy officer
ObsEva Appoints Katja Buhrer as Chief Strategy Officer
Why Elanco Animal Health Stock Is Falling Today
See More Headlines

Receive KIN Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Kindred Biosciences and its competitors with MarketBeat's FREE daily newsletter.

KIN Company Calendar

Last Earnings
8/05/2021
Today
8/14/2022

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:KIN
Fax
N/A
Employees
63
Year Founded
N/A

Profitability

Net Income
$-21,800,000.00
Net Margins
-529.26%
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
$42.16 million
Book Value
$1.75 per share

Miscellaneous

Free Float
N/A
Market Cap
$420.52 million
Optionable
Optionable
Beta
1.30

Key Executives














KIN Stock - Frequently Asked Questions

Should I buy or sell Kindred Biosciences stock right now?

1 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Kindred Biosciences in the last twelve months. There are currently 1 hold rating for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" KIN shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in KIN, but not buy additional shares or sell existing shares.
View KIN analyst ratings
or view top-rated stocks.

How were Kindred Biosciences' earnings last quarter?

Kindred Biosciences, Inc. (NASDAQ:KIN) released its earnings results on Thursday, August, 5th. The biopharmaceutical company reported ($0.20) earnings per share for the quarter, missing analysts' consensus estimates of ($0.16) by $0.04. The biopharmaceutical company had revenue of $3.54 million for the quarter, compared to analysts' expectations of $8.12 million. Kindred Biosciences had a negative trailing twelve-month return on equity of 54.19% and a negative net margin of 529.26%.

What other stocks do shareholders of Kindred Biosciences own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Kindred Biosciences investors own include CorMedix (CRMD), bluebird bio (BLUE), Sorrento Therapeutics (SRNE), Amicus Therapeutics (FOLD), Novavax (NVAX), Rigel Pharmaceuticals (RIGL), Inovio Pharmaceuticals (INO), OPKO Health (OPK), TherapeuticsMD (TXMD) and Agile Therapeutics (AGRX).

What is Kindred Biosciences' stock symbol?

Kindred Biosciences trades on the NASDAQ under the ticker symbol "KIN."

How much money does Kindred Biosciences make?

Kindred Biosciences (NASDAQ:KIN) has a market capitalization of $0.00 and generates $42.16 million in revenue each year. The biopharmaceutical company earns $-21,800,000.00 in net income (profit) each year or ($0.55) on an earnings per share basis.

How can I contact Kindred Biosciences?

Kindred Biosciences' mailing address is 1555 BAYSHORE HIGHWAY SUITE 200, BURLINGAME CA, 94010. The official website for the company is kindredbio.com. The biopharmaceutical company can be reached via phone at (650) 701-7901 or via email at ir@kindredbio.com.

This page (NASDAQ:KIN) was last updated on 8/14/2022 by MarketBeat.com Staff

MarketBeat Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | contact@marketbeat.com | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Privacy Policy | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see Barchart's disclaimer.